Literature DB >> 16181131

Positron Emission Tomography: applications in drug discovery and drug development.

Jingli Wang1, Laura Maurer.   

Abstract

Positron Emission Tomography (PET) is a sophisticated nuclear imaging modality that affords researchers the ability to conduct both functional and molecular imaging on biological and biochemical processes in vivo. In functional imaging, biological parameters such as metabolic rate and perfusion that can be altered by disease or treatment are monitored. In molecular imaging, PET can be used to examine and quantify cellular events such as cell trafficking, receptor binding and gene expression. Therefore, PET is an important tool to elucidate mechanisms associated with diseases and drug actions. In addition to PET, microPET is designed to image small animals. A great tool to facilitate preclinical studies and basic research, it can eliminate the need of sacrificing the animal by enabling noninvasive, longitudinal, and serial studies. The results from preclinical studies using microPET can be directly correlated with clinical studies using PET, thus bridging the chasm that used to separate the 2 pivotal phases in drug development. This review first describes the basic principles of PET and compares it to other imaging modalities. Then, PET procedures and PET isotopes and tracers synthesis are outlined. Next, functional and molecular PET imaging applications in the fields of oncology, neurology, and cardiology in both humans and animals are presented. Spanning a wide range, these applications demonstrate the versatility of PET and how it can be used to accelerate drug discovery and development. Finally, the advantages and limitations of PET and how it can be used in the future to minimize risks of drug development are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181131     DOI: 10.2174/156802605774297056

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  19 in total

1.  Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.

Authors:  Carmelo Quarta; Erika Cantelli; Cristina Nanni; Valentina Ambrosini; Daniela D'ambrosio; Korinne Di Leo; Silvia Angelucci; Federico Zagni; Filippo Lodi; Mario Marengo; William A Weiss; Andrea Pession; Roberto Tonelli; Stefano Fanti
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

2.  Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.

Authors:  Manuel Rodríguez-Garrido; Cristina Asensio-del-Barrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

3.  CNS animal fMRI in pain and analgesia.

Authors:  David Borsook; Lino Becerra
Journal:  Neurosci Biobehav Rev       Date:  2010-11-30       Impact factor: 8.989

4.  Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?

Authors:  David Borsook; Richard Hargreaves; Lino Becerra
Journal:  Expert Opin Drug Discov       Date:  2011-06-01       Impact factor: 6.098

Review 5.  Molecular imaging: current status and emerging strategies.

Authors:  M A Pysz; S S Gambhir; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

Review 6.  Recent development in PET instrumentation.

Authors:  By Hao Peng; Craig S Levin
Journal:  Curr Pharm Biotechnol       Date:  2010-09-01       Impact factor: 2.837

7.  Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.

Authors:  Tobias Hertlein; Volker Sturm; Udo Lorenz; K Sumathy; Peter Jakob; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Performance evaluation of an Inveon PET preclinical scanner.

Authors:  Cristian C Constantinescu; Jogeshwar Mukherjee
Journal:  Phys Med Biol       Date:  2009-04-21       Impact factor: 3.609

9.  Preclinical anaylses of [18F]cEFQ as a PET tracer for imaging metabotropic glutamate receptor type 1 (mGluR1).

Authors:  Boeun Lee; Yu Kyeong Kim; Ji Youn Lee; Young Joo Kim; Yun-Sang Lee; Dong Soo Lee; June-Key Chung; Jae Min Jeong
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 10.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.